The MGTX experience: Challenges in planning and executing an international, multicenter clinical trial

[1]  R. Conwit,et al.  Status of the Thymectomy Trial for Nonthymomatous Myasthenia Gravis Patients Receiving Prednisone , 2008, Annals of the New York Academy of Sciences.

[2]  S. Burris.  Regulatory Innovation in the Governance of Human Subjects Research: A Cautionary Tale and Some Modest Proposals , 2008 .

[3]  Salim Yusuf,et al.  Specific barriers to the conduct of randomized trials , 2008, Clinical trials.

[4]  F. Little,et al.  Myasthenia gravis in South Africans: Racial differences in clinical manifestations , 2007, Neuromuscular Disorders.

[5]  K. Teo,et al.  The role of the data coordinating center in the IRB review and approval process: the DIG trial experience. , 2003, Controlled clinical trials.

[6]  J. Newsom-Davis,et al.  Development of a Thymectomy Trial in Nonthymomatous Myasthenia Gravis Patients Receiving Immunosuppressive Therapy , 2003, Annals of the New York Academy of Sciences.

[7]  L. Phillips.  The Epidemiology of Myasthenia Gravis , 2003, Neurologic clinics.

[8]  J. Tavel,et al.  Regulatory approvals in a large multinational clinical trial: the ESPRIT experience. , 2002, Controlled clinical trials.

[9]  J. Torner,et al.  The epidemiology of myasthenia gravis in central and western Virginia , 1992, Neurology.

[10]  V. Wong,et al.  Myasthenia gravis in Hong Kong Chinese , 1992 .

[11]  V. Wong,et al.  Myasthenia gravis in Hong Kong Chinese: 2. Paediatric disease , 1992, Acta neurologica Scandinavica.

[12]  A. Vincent,et al.  Myasthenia gravis , 1987, Neurology.

[13]  A. Vincent,et al.  Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. , 1980, Brain : a journal of neurology.